Scott Kellen
Director of Finance/CFO chez DIAMEDICA THERAPEUTICS INC.
Fortune : 151 187 $ au 31/03/2024
Profil
Scott Kellen is currently the Chief Financial Officer & Secretary at DiaMedica Therapeutics, Inc. He previously worked as the Finance Director at Transoma Medical, Inc. from 2007 to 2009, the Controller at ev3, Inc. from 2005 to 2007, and the COO, CFO, Secretary, VP & Head-Investor Relations at Kips Bay Medical, Inc. from 2012 to 2015.
Scott also served as the Chief Financial Officer & Vice President at Sun Biopharma, Inc. Additionally, he worked as a Senior Audit Manager at Deloitte & Touche LLP from 1987 to 2005.
Mr. Kellen holds an undergraduate degree from the University of South Dakota.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 25/03/2024 | 32 290 ( 0,09% ) | 89 443 $ | 31/03/2024 | |
| 01/06/2022 | 22 290 ( inf% ) | 61 743 $ | 31/03/2024 |
Postes actifs de Scott Kellen
| Sociétés | Poste | Début |
|---|---|---|
| DIAMEDICA THERAPEUTICS INC. | Director of Finance/CFO | 01/04/2018 |
Anciens postes connus de Scott Kellen
| Sociétés | Poste | Fin |
|---|---|---|
| PANBELA THERAPEUTICS, INC. | Director of Finance/CFO | 01/04/2018 |
Transoma Medical, Inc.
 Transoma Medical, Inc. Medical/Nursing ServicesHealth Services Transoma Medical, Inc., headquartered in St. Paul, Minnesota, is a medical technology company engaged in developing, manufacturing and distributing implantable, wireless diagnostic and monitoring systems. Transoma is focused specifically on diagnostic and monitoring technology and dedicated to providing physicians with information needed to accurately and quickly diagnose unexplained, infrequent symptoms and to monitor changing, often asymptomatic complex arrhythmias. Transoma has an extensive technology platform based on more than 20 years experience in developing implantable wireless diagnostic systems for use in biomedical research. These innovative tools have played a key role in drug discovery, pre-clinical evaluation of safety and efficacy, and other academic and government basic research. Customers have turned to DSI for more accurate, timely physiological data, highly humane research practices, and faster times to market. In 2003 the Patient Management division was formed utilizing this proven technology platform and paving the way for the formation of Transoma Medical. | Director of Finance/CFO | 01/05/2009 |
ev3, Inc.
 ev3, Inc. Medical SpecialtiesHealth Technology ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support. | Comptroller/Controller/Auditor | 01/10/2007 |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Comptroller/Controller/Auditor | 01/04/2005 |
| Sun Biopharma, Inc. /Old/ | Director of Finance/CFO | - |
Formation de Scott Kellen
| University of South Dakota | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DIAMEDICA THERAPEUTICS INC. | Health Technology |
| PANBELA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
ev3, Inc.
ev3, Inc. Medical SpecialtiesHealth Technology ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support. | Health Technology |
Kips Bay Medical, Inc.
 Kips Bay Medical, Inc. Medical SpecialtiesHealth Technology Kips Bay Medical, Inc. was a medical device company focused on developing, manufacturing and commercializing its proprietary external saphenous vein support technology for use in coronary artery bypass grafting surgery. Its product, eSVS MESH, was a nitinol mesh sleeve that was placed over the saphenous vein graft during CABG surgery and is designed to constrict the vein and prevent expansion of the vein graft and resulting injury due to increased pressure. The company was founded by Manuel A. Villafaña on May 1, 2007 and was headquartered in Minneapolis, MN. | Health Technology |
| Sun Biopharma, Inc. /Old/ | Health Technology |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
Transoma Medical, Inc.
Transoma Medical, Inc. Medical/Nursing ServicesHealth Services Transoma Medical, Inc., headquartered in St. Paul, Minnesota, is a medical technology company engaged in developing, manufacturing and distributing implantable, wireless diagnostic and monitoring systems. Transoma is focused specifically on diagnostic and monitoring technology and dedicated to providing physicians with information needed to accurately and quickly diagnose unexplained, infrequent symptoms and to monitor changing, often asymptomatic complex arrhythmias. Transoma has an extensive technology platform based on more than 20 years experience in developing implantable wireless diagnostic systems for use in biomedical research. These innovative tools have played a key role in drug discovery, pre-clinical evaluation of safety and efficacy, and other academic and government basic research. Customers have turned to DSI for more accurate, timely physiological data, highly humane research practices, and faster times to market. In 2003 the Patient Management division was formed utilizing this proven technology platform and paving the way for the formation of Transoma Medical. | Health Services |
